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Effect of universal MODS access on pulmonary tuberculosis 
treatment outcomes in new patients in Peru
A. Mendoza-Ticona,1 E. Alarcón,2 V. Alarcón,3 K. Bissell,2,4 E. Castillo,5 I. Sabogal,6 J. Mora,5 
D. Moore,7 A. D. Harries2,7
ally in 1–3 weeks, and low cost, the WHO recom-
mended its implementation in developing countries.8 
In 2008, the National TB Programme (NTP) and the 
National Institute of Health started implementing uni-
versal access to the MODS assay in some regions in 
Lima and Callao.9 Universal access means that MODS 
is used for every patient (new and previously treated, 
smear-positive and smear-negative) about to start anti-
tuberculosis treatment. However, the NTP has not yet 
evaluated the impact of this intervention and whether 
it is associated with improved TB treatment manage-
ment, processes and outcomes. 
To our knowledge, MODS has not been implemented 
within the public health system in any other country, 
and there is no published information about whether 
or not this intervention is beneﬁ cial for patient man-
agement and outcomes under routine conditions. Our 
hypothesis is that MODS reduces the delay in diagnos-
ing drug-susceptible and MDR-TB, accelerates the ad-
ministration of correct treatment and improves anti-
tuberculosis treatment outcomes. 
The primary objective was to determine whether 
treatment outcomes among new smear-positive or 
smear-negative/culture-positive pulmonary TB (PTB) 
patients starting ﬁ rst-line anti-tuberculosis treatment 
(termed Regimen I) improved following the introduc-
tion of MODS. Secondary objectives were to compare, 
before and after the introduction of MODS: 1) DST 
coverage, MDR-TB case detection and time taken to 
diagnose drug-susceptible, INH-resistant and MDR-TB, 
and 2) the treatment outcomes of MDR-TB patients di-
agnosed in the Callao region. 
METHODS
Study design
This was a retrospective cross-sectional study assessing 
two cohorts of adults with newly diagnosed smear- or 
culture-positive PTB.
Setting 
General
Peru (population: 29 million) is a large country in Latin 
America with a gross domestic product of US$8825 
per capita. Peru began its DOTS-based TB Control Pro-
gramme in 1991, and managed to meet WHO targets 
for case detection and cure for smear-positive PTB.10 De-
spite these successes, MDR- and XDR-TB have emerged 
as signiﬁ cant public health problems for the NTP to ad-
dress. Patients with suspected TB are diagnosed and reg-
istered according to national TB guidelines.11 Patients 
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Setting: Primary health care centres in Callao, Peru.
Objectives: To evaluate the effect of universal access to 
the microscopic-observation drug susceptibility (MODS) as-
say on treatment outcomes in new and primary multidrug-
resistant tuberculosis (MDR-TB) patients and on the pro-
cess of drug susceptibility testing (DST).
Design: Retrospective review of tuberculosis (TB) regis-
ters and clinical records before (2007) and after (2009) 
the introduction of MODS in 2008.
Results: There were 281 patients in each cohort. Favour-
able treatment outcomes for 2007 (81%) and 2009 (77%) 
cohorts were similar. There was an increase in loss to 
follow-up (from 6% to 10%, P = 0.04) and a reduction in 
failure rates (from 4% to 0.4%, P = 0.01) in the 2009 com-
pared with the 2007 cohort. In new MDR-TB cases (n = 
22), a favourable treatment outcome was improved (from 
46% to 82%, P = 0.183) in the 2009 cohort. DST cover-
age improved (from 24% to 74%, P < 0.001), and a sig-
nificant reduction in time to diagnosis of drug-susceptible 
(from 118 to 33 days, P < 0.001) and MDR-TB (from 158 
to 52 days, P = 0.003) was observed in the 2009 cohort.
Conclusion: Universal access to MODS increased DST 
coverage, reduced the time required to obtain DST re-
sults and was associated with reduced failure rates. MODS 
can make an important contribution to TB management 
and control in Peru.
Peru has a high burden of drug-resistant tuberculo-sis (TB): of an estimated 34 000 TB cases per an-
num, 2600 new multidrug-resistant TB (MDR-TB, resis-
tant to at least isoniazid [INH] and rifampicin [RMP]) 
cases and around 120 new extensively drug-resistant 
TB (XDR-TB) cases are estimated to occur annually.1–3 
The most recent national survey in Peru showed that 
5.3% of TB patients in the country and 8.6% in the 
Lima and Callao regions have primary MDR-TB.3 To 
reduce the failure and relapse rates of the empiric 
short regimens proposed by the World Health Organi-
zation (WHO) and accelerate the early diagnosis of 
MDR-TB, it has been recommended that in settings 
where the MDR-TB rate among new cases is over 3%, 
drug susceptibility testing (DST) should be performed 
for all patients as soon as TB is diagnosed.4,5
The MODS (microscopic observation drug suscepti-
bility) assay was developed in Peru in 2000 as a rapid 
test to diagnose Mycobacterium tuberculosis and assess 
susceptibility to INH and RMP simultaneously using a 
liquid culture set and inverted microscopy.6,7 Based on 
its good performance, including rapid diagnosis usu-
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are treated with national ﬁ rst-line and retreatment regimens ac-
cording to category of TB and risk factors for drug-resistant TB. 
New patients receive the 6-month Regimen I, which consists of a 
2-month initial phase of daily INH, RMP, pyrazinamide and eth-
ambutol, followed by a 4-month continuation phase of twice-
weekly RMP and INH. Those at high risk of MDR-TB are treated 
with a standardised MDR-TB regimen, followed by individualised 
regimens once culture and DST results are available. MDR-TB 
treatment lasts 18–24 months, depending on culture results dur-
ing treatment. 
Management of patients starting Regimen I 
before and after introduction of MODS 
Protocols for managing patients starting Regimen I before and 
a fter the introduction of MODS are shown in Table 1.11,12
Study site
The Dirección Regional de Salud Callao was selected, as MODS was 
implemented in the Regional TB Laboratory in August 2008; DST 
was previously performed only at the National TB Laboratory in 
Lima. MODS is currently offered to smear-positive and -negative 
PTB patients before treatment initiation. MODS results are ob-
tained via internet through the NETLAB system (Instituto Nacio-
nal de Salud, Lima, Peru) 7–21 days after sputum submission. 
NETLAB’s database includes all persons tested in Peru’s regional 
and national TB laboratories. 
The Callao region (population: 941 268) has the same metro-
politan area as Lima, the capital city, a TB case notiﬁ cation rate of 
127 cases per 100 000 population, a smear-positive TB case notiﬁ -
cation rate of 72 cases/100 000 and an MDR-TB rate among new 
patients of approximately 6%. Most TB patients are treated in the 
public sector, with <5% treated in the private sector.13 Callao has 
45 primary health care centres organised in three health networks: 
BEPECA (Bellavista, La Perla and Carmen de la Legua Districts), 
Bonilla and Ventanilla, two district hospitals and one central hos-
pital, all with a TB out-patient clinic. Human immunodeﬁ ciency 
virus (HIV) prevalence in TB patients is low, at 1–3%, similar to 
the rest of the country.14 
This study focused on TB out-patient clinics from the BEPECA 
and Bonilla Health Networks, with 15 and 17 TB clinics, respec-
tively. As the MODS assay had been validated in Ventanilla since 
2005, it was excluded from this evaluation.
Study population
We included all patients from two cohorts: 1) adults (aged 
⩾15 years) with new smear-positive or smear-negative/culture-
positive PTB registered in 2007 in the BEPECA and Bonilla Net-
works before the introduction of MODS, and 2) adults (aged 
⩾15 years) with new smear-positive or smear-negative/culture-
positive PTB registered in 2009 in the BEPECA and Bonilla Net-
works, after the introduction of MODS in 2008. 
Data variables, sources and collection
A trained team collected data directly from the TB patient regis-
ters in each TB clinic using a structured questionnaire (January–
April 2012). The clinical records and TB cards of patients that met 
the inclusion criteria in each cohort were reviewed. Variables in-
cluded TB registration number, age, sex, date of TB diagnosis and 
treatment initiation, smear microscopy results, whether there was 
irregular treatment in the initial or continuation phases of treat-
ment (at least one dose not taken on the correct date), ﬁ nal treat-
ment outcomes on Regimen I, INH and RMP susceptibility proﬁ le, 
number of patients diagnosed with MDR-TB while on Regimen I, 
number of patients started on MDR-TB treatment (deﬁ ned as em-
pirical standardised MDR-TB treatment), ﬁ nal outcome of MDR-
TB patients, and dates of diagnosis and treatment processes for 
drug-susceptible and drug-resistant TB. 
Regarding the ﬁ nal treatment outcomes on Regimen I, we in-
cluded an outcome category ‘initial TB treatment not completed’ 
to include patients whose Regimen I treatment was stopped due 
to adverse reactions or diagnosis or suspicion of drug-resistant TB, 
as described above. Data on DST (MODS and conventional pro-
portion method) were obtained from patient clinical ﬁ les and 
from NETLAB.
Analysis and statistics
Data were double-entered into EpiData 3.1 (EpiData Association, 
Odense, Denmark), and then transferred to STATA 10 (Stata Corp, 
College Station, TX, USA). We compared the two cohorts in rela-
tion to 1) general characteristics; 2) diagnosis of MDR-TB; 3) ﬁ nal 
treatment outcomes, including the category ‘initial TB treatment 
not completed’; and 4) time to diagnosis and the various decisions 
about treatment options for drug-susceptible and drug-resistant 
TB. Continuous variables were compared between the two cohorts 
using the Mann-Whitney test. Categorical variables were com-
pared using the χ2 test or Fisher’s exact test if at least one value 
was <5. Signiﬁ cance levels were set at 5%. 
Ethics approval
The protocol was approved by the Ethics Committees of the Inter-
national Union Against Tuberculosis and Lung Disease in Paris, 
TABLE 1 Management of patients starting Regimen I before and 
after the introduction of MODS
Management of patients starting Regimen I before the introduction 
of MODS 
Smear-positive pulmonary TB patients starting Regimen I treatment are 
first assessed for high risk of MDR-TB according to national guidelines.10 
If they are at high risk, sputum culture in Ogawa and Löwenstein-
Jensen media and DST (proportion by Canetti method) are carried out. 
If DST shows the presence of MDR-TB, patients are taken off Regimen I 
treatment and started on MDR-TB treatment. All other patients have 
sputum smear examinations performed at Month 2. If patients are 
smear-negative, they continue on the initial treatment regimen and 
sputum smears are examined at 4 and 6 months. If patients are smear-
positive at 2 months, they are evaluated by a local TB consultant and a 
decision is made to continue Regimen I or to declare the patient a 
‘drug-resistant TB suspect’ according to clinical and epidemiological 
criteria: in both cases, sputum is obtained for culture and DST. Patients 
suspected of having drug-resistant TB are started on empirical 
standardised MDR-TB treatment. This is changed to individualised 
MDR-TB treatment or back again to Regimen I based on DST results. 
Patients in Regimen I with positive smears at 4 and 6 months are 
declared failures, sputum is obtained for culture and DST, and patients 
are started on empirical standardised MDR-TB treatment, followed by 
individualised treatment based on DST results
Management of patients starting Regimen I after the introduction 
of MODS 
Before starting Regimen I, all pulmonary TB patients (smear-positive, 
smear-negative, never treated and previously treated) submit sputum 
specimens for MODS examination. If the MODS test shows MDR-TB, 
the patients are taken off Regimen I treatment and started on MDR-TB 
treatment. If the MODS test shows no resistance to isoniazid and 
rifampicin, the patients stay on the initial Regimen I treatment. If the 
MODS test shows drug resistance patterns different to MDR-TB, 
treatment may be modified according national guidelines11 
MODS = microscopic observation drug susceptibility test; TB = tuberculosis; MDR-
TB = multidrug-resistant TB (i.e., Mycobacterium tuberculosis with resistance to at 
least isoniazid and rifampicin); DST = drug susceptibility testing.
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France, and the Instituto de Medicina Tropical of the Universidad 
Nacional Mayor de San Marcos in Lima, Peru. 
RESULTS
Baseline characteristics of patients
Of 680 eligible patients, 562 (83%) were included in the study. 
Each cohort had 281 patients, equally distributed between the 
health networks (Figure). The demographic and clinical character-
istics of the two cohorts are shown in Table 2. There were no dif-
ferences in age or sex. HIV status was evaluated more frequently 
in the 2009 cohort, but the proportion of HIV-positive patients 
was similar, at <3%. There was a higher proportion of smear-
negative, culture-positive TB patients and a lower proportion of 
patients with grade 3+ positive smears in the 2009 cohort.
Treatment outcomes of patients on Regimen I
Treatment outcomes are shown in Table 3. No difference in fa-
vourable outcomes (cure or treatment completed) between the 
2007 and 2009 cohorts on Regimen I was observed. There was a 
signiﬁ cant reduction in treatment failure (P = 0.011); however, 
loss to follow-up increased signiﬁ cantly in the 2009 compared with 
the 2007 cohort (P = 0.04). Treatment regularity was assessed: 
23% of each cohort had a record of at least one dose of medica-
tion missed in the initial phase of treatment, and respectively 
40% and 35% of the 2007 and 2009 cohort had a record of at 
least one dose of medication missed in the continuation phase of 
treatment; these differences were not signiﬁ cant. 
Drug susceptibility testing and MDR-TB case detection
DST results are shown in Table 4. DST coverage was higher in the 
2009 group (24% vs. 74%, P < 0.001), but the proportion of pa-
tients ultimately diagnosed with MDR-TB was similar in both 
cohorts. Time taken from diagnosis of TB to diagnosis of drug-
susceptible, INH-resistant or MDR-TB is shown in Table 5. For 
drug-susceptible and drug-resistant TB, there was a signiﬁ cant re-
duction in the number of days to diagnosis in the 2009 compared 
with the 2007 cohort. For MDR-TB, the time between TB diagno-
sis and MDR-TB treatment initiation was 2.5 months (interquartile 
range [IQR] 1.3–3.0) in the 2009 cohort, signiﬁ cantly shorter than 
the 5.7 months (IQR 4.3–7.9) in the 2007 cohort (P < 0.001). 
Treatment outcome of MDR-TB 
Of cases discharged as ‘drug-resistant TB suspect’, seven in 2007 
and ﬁ ve in 2009 were diagnosed with MDR-TB. There were a ﬁ nal 
24 patients with MDR-TB, 11 in the 2007 cohort and 13 in the 
FIGURE Flow diagram of participants included in cohort before 
(2007) and after (2009) the introduction of the MODS assay, Callao, 
Peru. BEPECA network = Bellavista, La Perla and Carmen de la Legua 
Districts; Bonilla network = Callao and La Punta Districts; MODS = 
microscopic observation drug susceptibility.
TABLE 2 Demographic and clinical characteristics of TB patients 
before (2007) and after (2009) the introduction of the MODS assay, 
Callao, Peru 
Characteristic
2007 
(n = 281)
n (%) 
2009 
(n = 281)
n (%) P value* 
Age, years, median 
  [1st and 3rd quartiles] 33.7 [21, 42] 34.5 [21, 45]   0.55
 15–30
 31–45
 46–60
 >60
164 (58)
 59 (21)
 33 (12)
 25 (9)
152 (54)
 59 (21)
 47 (17)
 23 (8)
  0.39
Female sex 115 (41) 111 (40)   0.73
HIV status
 Evaluated 
 Positive 
184 (66)
  3 (1.6)
226 (80)
  8 (3.5)
<0.001
  0.23
Result of smear microscopy
 Negative (culture +)
 Positive +
 Positive ++
 Positive +++
 Scanty
  3 (1)
 93 (33)
 99 (35)
 85 (30)
  1 (0.4)
 38 (14)
 91 (32)
 94 (34)
 54 (19)
  4 (1)
<0.001
  0.86
  0.66
  0.002
  0.37
* Mann-Whitney test.
TB = tuberculosis; MODS = microscopic observation drug susceptibility; HIV = 
h uman immunodeficiency virus.
TABLE 3 Final treatment outcomes of Regimen I in TB patients 
before (2007) and after (2009) the introduction of the MODS assay, 
Callao, Peru
Outcome
2007 
(n = 281)
n (%) 
2009 
(n = 281)
n (%) P value*
Favourable outcome 227 (81) 216 (77) 0.258
 Cure 214 (76) 207 (74)
 Treatment completed  13 (5)   9 (3)
Poor outcome  29 (10)  32 (11) 0.684
 Failure  10 (4)   1 (0.4) 0.011*
 Died   3 (1)   2 (1) 1.00
 Loss to follow-up (default)  16 (6)  29 (10) 0.043
Other outcomes  25 (9)  33 (12)
 Transfer out   8 (3)   9 (3) 0.805
 Initial TB treatment not completed  17 (6)  24 (9) 0.256
Reasons for initial TB treatment not 
  being completed†
 Adverse drug reactions
 MDR-TB diagnosis
 INH- or RMP-resistant/TB diagnosis
 Drug-resistant TB suspect
  3 (1.1)
  4 (1.4)
  2 (0.8)
  8 (2.8)
  1 (0.4)
  8 (2.9)
  9 (3.2)
  6 (2.1)
* Fisher’s exact test.
†Respectively seven and five cases were confirmed as MDR-TB in the 2007 and 2009 
cohorts. 
TB = tuberculosis; MODS = microscopic observation drug susceptibility; MDR-TB = 
multidrug-resistant TB; INH = isoniazid; RMP = rifampicin.
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2009 cohort. Treatment outcomes are shown in Table 6. Two pa-
tients in the 2009 cohort were still on treatment during data col-
lection and thus ﬁ nal treatment outcomes were unavailable. For 
the remaining 22 patients, a favourable outcome was more fre-
quent in the 2009 cohort (46% vs. 82%, P = 0.183).
DISCUSSION
There have been no previous evaluations of the effect of universal 
access to the MODS assay in Peru since its implementation in 
2008. This is the ﬁ rst study to assess its usefulness under routine 
conditions in the Callao region of Peru. We found that universal 
access to MODS contributed signiﬁ cantly to increasing DST cover-
age and reducing the time taken between the diagnosis of TB and 
receipt of DST results. 
Although universal access to MODS failed to improve the over-
all ﬁ nal treatment outcomes of new patients with PTB on Regi-
men I or patients with MDR-TB diagnosed during Regimen I treat-
ment, failure rates during Regimen I were signiﬁ cantly reduced by 
using MODS. This is an important advantage, as it allows such pa-
tients to be changed much earlier to an appropriate regimen. How-
ever, despite the policy of universal access to MODS, only 60% of 
the 2009 cohort accessed it. The main reasons for this deﬁ ciency 
were 1) difﬁ culties in local transportation of samples; 2) poor quan-
tity and quality of sputum specimens; and 3) failure of health care 
staff to comply with guidelines due to high staff turnover. 
The impact of any new diagnostic test depends entirely on the 
effective functioning of the overall programme. Unfortunately, 
the 2009 cohort with MODS had a high loss to follow-up, which 
reduced the group’s overall treatment success. This increased loss 
to follow-up is not limited to patients in this study; it is a general 
phenomenon recorded in the TB programme in Callao. Reasons 
include 1) increasing rates of drug-resistant TB in patients being 
treated in primary health care centres that do not have sufﬁ cient 
health care workers, 2) high proportions of drug and alcohol use 
in the region, and 3) anti-social behaviour of patients, leading to 
imprisonment or disappearance from the health system.15
Another important issue evaluated was the high proportion of 
patients with poor treatment adherence in both cohorts, which is 
a precursor to patients being declared lost to follow-up. We be-
lieve that there is a need for an international operational deﬁ ni-
tion of ‘irregular treatment’ so that these events can be closely 
monitored and interventions to prevent loss to follow-up may be 
implemented. Peru’s NTP will need to address this signiﬁ cant na-
tionwide problem. This is especially important in Peru as the con-
tinuation phase includes medication given only twice weekly, 
which means that loss of a single dose can lead to subtherapeutic 
drug concentrations and thus an increased risk of drug resistance.
Study strengths include the large number of patients in each 
group, evaluations performed within the routine system, and 
study conduct and write-up per STROBE (Strengthening the Re-
porting of Observational Studies in Epidemiology) guidelines.16 
Limitations are those of any retrospective study, and the fact that 
17% of patients could not be assessed due to absent or poorly 
completed medical records. 
The study had small numbers of MDR-TB patients, and despite 
the better outcomes in the 2009 cohort, there was limited power to 
show any signiﬁ cant differences compared with the 2007 cohort. 
This ﬁ nding should be evaluated taking into account all MDR-TB 
cases in both cohorts, and not only newly detected cases. 
There is no previous literature about the use of MODS by rou-
tine health systems. The WHO currently recommends the use of 
Xpert® MTB/RIF (Cepheid, Sunnyvale, CA, USA) for patients with 
suspected HIV-associated TB or MDR-TB.17,18 While Xpert is an 
important and revolutionary new diagnostic test that requires 
minimal laboratory expertise and produces results for TB diag-
nosis and RMP resistance within 2 h, and despite the subsidised 
cost of less than US$10 per cartridge,19 the main challenge for 
Peru is the necessity to conﬁ rm INH susceptibility in Xpert RMP-
s usceptible cases.20 In Lima and Callao, the prevalence of primary 
resistance to INH is 16.4%, while only 8.1% of samples are also re-
sistant to RMP (MDR-TB).3 Xpert is also recommended in high 
HIV prevalence settings, but fortunately, and unlike the situation 
in many African countries, the prevalence of co-infection of HIV 
among persons with TB is <3% in Peru.14 Instead of using Xpert, 
TABLE 4 DST and MDR-TB case detection of TB patients before 
(2007) and after (2009) the introduction of the MODS assay, 
Callao, Peru
Characteristic
2007 
(n = 281)
n (%)
2009 
(n = 281)
n (%) P value
DST
 MODS assay
 Proportion method
 Other (BACTEC™ 460)
66 (24)
 0 
63 (95)
 3 (5)
207 (74)
169 (82)
 38 (18)
  0 
<0.001
MDR-TB diagnosed 11 (4)  13 (5)   0.676
DST = drug susceptibility testing; MDR-TB = multidrug-resistant tuberculosis; 
MODS = microscopic observation drug susceptibility.
TABLE 5 Time taken from the diagnosis of TB to the diagnosis of 
drug-susceptible, INH-resistant or MDR-TB before (2007) and after 
(2009) the introduction of the MODS assay, Callao, Peru
Type of TB
2007
n (%) or
median [IQR]* 
2009
n (%)  or
median [IQR]* P value
Drug-susceptible TB
Time to diagnose 
drug-susceptible TB, days
43 (15)
118 [101–131]
174 (62)
33 [16–27]
<0.001
<0.001
INH-resistant TB (non-MDR-TB) 
Time to diagnose 
INH-resistant TB, days
 9 (3)
 92.7 [86–107]
 18 (6)
49.4 [20–69]
  0.073
  0.006
MDR-TB
Time to diagnose 
MDR-TB, days
11 (4)
157.5 [93–211]
 13 (5)
51.6 [13–80]
  0.663
  0.003
* Data are median and [first and third quartiles] unless stated otherwise. 
TB = tuberculosis; INH = isoniazid; MDR-TB = multidrug-resistant TB; MODS = mi-
croscopic observation drug susceptibility; IQR = interquartile range.
TABLE 6 Final treatment outcomes of MDR-TB patients before 
(2007) and after (2009) the introduction of the MODS assay, 
Callao, Peru
Outcome
2007
(n = 11)
n (%) 
2009
(n = 11)
n (%) P value
Favourable outcome 5 (46) 9 (82) 0.183*
 Cure 5 (46) 7 (64)
 Treatment completed 0 2 (18)
Poor outcome 6 (55) 2 (18)
 Treatment failure 0 0 
 Died 1 (9.0) 0 
 Default 5 (46) 2 (18)
* Comparison between 2007 and 2009. 
MDR-TB = multidrug-resistant tuberculosis; MODS = microscopic observation drug 
susceptibility.
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Peru is the ﬁ rst country in Latin America to implement Geno-
type® MTBDRplus (Hain Lifesciences, Nehren, Germany) as part of 
its public health policy at the National Laboratory of Mycobacteria 
in combination with the MODS assay implemented in several re-
gions.21 Both tests address the issue of INH and RMP susceptibil-
ity; MODS can be used for patients with smear-negative TB and in 
HIV-infected patients. In Peru, the cost of one test using MODS is 
approximately US$5,22 and an inverted microscope costing less 
than US$1000 is required. 
In conclusion, this study shows the feasibility and advantage of 
using the MODS assay in all new patients at treatment initiation. 
Although ﬁ nal treatment outcomes were not signiﬁ cantly modiﬁ ed 
with MODS, this test makes a contribution to earlier detection, 
better management and prevention of drug-resistant TB transmis-
sion in the country. It is critical that the Peruvian NTP implement 
interventions to address poor drug adherence and loss to follow-
up as fundamental measures for the prevention and control of 
drug-resistant TB, irrespective of which rapid test is implemented. 
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 Contexte  :  Les centres primaires de soins de santé à Callao, Pérou.
Objectifs  :  Evaluer l’effet d’un accès général au test d’observation 
m icroscopique de la sensibilité aux médicaments (MODS) sur les ré-
sultats du traitement chez les nouveaux patients et dans les cas de tu-
berculose où existe une multirésistance TB primaire ainsi que sur le 
processus des tests de sensibilité aux médicaments. 
Schéma  :  Revue rétrospective des registres TB et des dossiers cliniques 
avant l’introduction du MODS en 2008, en l’occurrence en 2007 et 
après celle-ci, en l’occurrence en 2009. 
Résultats  :  Chaque cohorte comportait 281 patients. Les résultats fa-
vorables du traitement ont été similaires en 2007 (81%) et en 2009 
(77%). On a noté une augmentation des pertes de suivi (passant de 
6% à 10% ; P = 0,04) et une diminution des échecs (passant de 4% 
à 0,4% ; P = 0,01) dans la cohorte de 2009 par comparaison à celle 
de 2007. Parmi les 22 nouveaux cas de TB-MDR, le résultat favorable 
du traitement a été plus fréquent (passant de 46% à 82% ; P = 
0,183) dans la cohorte de 2009. Dans la cohorte de 2009, on a noté 
une meilleure couverture par les tests de sensibilité aux médicaments 
(passant de 24% à 74% ; P < 0,001) ainsi qu’une réduction significa-
tive de la durée précédant le diagnostic chez les patients sensibles 
aux médicaments (passant de 118 à 33 jours ; P < 0,001) et chez les 
patients atteints de TB-MDR (passant de 158 à 52 jours ; P = 0,003). 
Conclusion : Un accès général au MODS augmente la couverture en 
matière de tests de sensibilité, réduit la durée avant l’obtention des 
résultats de la sensibilité et est en association avec une décroissance 
des taux d’échec. Le MODS peut constituer une contribution impor-
tante à la prise en charge et à la lutte contre la TB au Pérou.
 
Marco de referencia: Los centros de atención primaria de salud en 
Callao, Perú.
Objetivos: Evaluar la repercusión del acceso universal a la prueba de 
observación microscópica de la sensibilidad a los medicamentos 
(MODS) en el desenlace de los casos nuevos de tuberculosis multi-
drogorresistente (TB-MDR) primaria y en el procedimiento de evalua-
ción de la sensibilidad.
Método: Se llevó a cabo un examen retrospectivo de los registros de 
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TB y de las historias clínicas en el 2007 antes de la introducción de la 
técnica MODS, que tuvo lugar en el 2008 y después de la misma 
(2009).
Resultados: Cada cohorte constó de 281 pacientes. Los desenlaces 
terapéuticos favorables fueron equivalentes en las cohortes del 2007 
(81%) y el 2009 (77%). Se observó un aumento en la pérdida de ca-
sos durante el seguimiento (de 6% a 10%; P = 0,04) y una dismi-
nución de los fracasos terapéuticos (de 4% a 0,4%; P = 0,01) en la 
cohorte del 2009, comparada con la cohorte del 2007. En 22 casos 
nuevos de TB-MDR se mejoró el desenlace terapéutico en la cohorte 
del 2009 (de 46% a 82%; P = 0,183). En la cohorte del 2009, se 
logró una mejor cobertura con las pruebas de sensibilidad a los medi-
camentos (de 24% a 74%; P < 0,001) y una disminución significativa 
del lapso hasta la obtención del diagnóstico de TB farmacosensible 
(de 118 a 33 días; P < 0,001) y de TB-MDR (de 158 a 52 días; P = 
0,003).
Conclusión: El acceso universal a la técnica MODS amplía la cober-
tura de evaluación de la sensibilidad a los medicamentos, disminuye 
el lapso hasta la obtención de los resultados de la prueba y se asocia 
con una disminución de las tasas de fracaso terapéutico. La prueba 
MODS puede contribuir de manera considerable al tratamiento y al 
control de la TB en el Perú.
